drugset / Trial / NCT00189293

Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts

NCT00189293

Phase 4 Completed 128 enrolled MEDA Pharma GmbH & Co. KG
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the recurrence rate following total clearance of external genital warts (EGWs) when clearance has been obtained by imiquimod (3 applications per week for 4 weeks) followed by ablative therapy (laser or electrocautery therapy) with that from just ablative therapy treatment alone.

Timeline

Start
2005-06
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Imiquimod Other / unclassified 5 %